| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 164.300 | 161.498 | 177.127 | 181.380 | 182.281 | 200.420 | 209.102 | 237.383 | 300.725 | 399.872 |
| Total Income - EUR | 164.524 | 161.744 | 178.034 | 181.953 | 182.914 | 200.764 | 209.427 | 241.846 | 303.010 | 400.147 |
| Total Expenses - EUR | 165.255 | 159.925 | 176.866 | 175.254 | 176.995 | 197.086 | 205.234 | 234.273 | 287.841 | 376.967 |
| Gross Profit/Loss - EUR | -730 | 1.819 | 1.168 | 6.698 | 5.919 | 3.678 | 4.193 | 7.574 | 15.169 | 23.180 |
| Net Profit/Loss - EUR | -730 | 1.627 | -532 | 4.879 | 4.090 | 1.670 | 2.099 | 5.155 | 12.673 | 19.443 |
| Employees | 2 | 2 | 2 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Check the financial reports for the company - Antipiretica Impex Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 33.879 | 43.792 | 42.884 | 55.466 | 55.287 | 67.483 | 72.109 | 76.880 | 115.089 | 126.286 |
| Inventories | 15.811 | 21.378 | 14.347 | 14.386 | 20.155 | 22.007 | 22.726 | 26.699 | 42.719 | 51.272 |
| Receivables | 14.182 | 7.338 | 24.352 | 38.315 | 29.368 | 40.381 | 46.458 | 47.458 | 57.551 | 49.127 |
| Cash | 3.886 | 15.075 | 4.185 | 2.765 | 5.763 | 5.095 | 2.926 | 2.723 | 14.820 | 25.886 |
| Shareholders Funds | -676 | 958 | -479 | 4.408 | 4.141 | 1.720 | 2.147 | 5.204 | 12.722 | 19.492 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 34.556 | 42.834 | 43.364 | 51.058 | 51.146 | 65.763 | 69.962 | 71.676 | 102.368 | 106.794 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Antipiretica Impex Srl